Digoxin After Acute Heart Failure (DIG-DICA)

The DIG-DICA trial is a randomized, controlled, open-label, single-center study designed to evaluate whether adding low-dose digoxin to optimal medical therapy after an episode of acute decompensated heart failure improves patients' clinical status and quality of life. The study enrolls adults with heart failure with reduced ejection fraction (HFrEF) who have recently stabilized after hospitalization or urgent care for decompensation. The primary aim is to determine whether digoxin increases the proportion of patients who are "Alive and Well" at 180 days-defined by achieving a Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score ≥75. The trial also explores effects on symptoms, functional capacity, biomarkers, renal function, and major cardiovascular events. The goal is to clarify whether modern low-dose digoxin provides meaningful clinical benefit in contemporary heart failure management.

NCT Number	NCT07321509
Lead Sponsor	Hospital General de Agudos "Dr. Cosme Argerich"
Conditions	Acute Heart Failure (AHF)
Enrollment	120 participants
Start Date	2025-12-16
Primary Completion	2027-12-16 (estimated)
Study Completion	2028-12-16 (estimated)
Updated on ClinicalTrials.gov	2026-06-02